These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2007-003369-42 Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interfé... 2012-01-13 due-trials
Ongoing 2007-007968-19 Evaluation comparative, en double aveugle, de l'efficacité d'infiltrations locales per et post opératoires de ropivacaïne dans la prise en charge de la douleur après chirurgie hépatique chez l'adulte not-yet-due
Ongoing 2008-002138-31 Evaluation de l'efficacité, de la tolérance et analyse médico-économique d'une administration unique de Pegfilgrastim dans les Autogreffes de cellules souches périphériques chez des patients atteints ... not-yet-due
Reported results 2009-009867-70 Evaluation, chez des femmes atteintes d’un cancer du sein non métastatique recevant un traitement antihormonal adjuvant, de l’efficacité d’un traitement homéopathique par BRN-01 versus placebo dans le... 2014-04-10 due-trials
Ongoing 2009-009899-12 Evaluation chez l’enfant et l’adulte présentant une rechute d’ostéosarcome de l’efficacité et de la tolérance d’un traitement adjuvant par Thiotépa® haute dose associé à une chimiothérapie conventionn... not-yet-due
Ongoing 2009-011280-37 Efficacy and safety assessment of oral LBH589 in adult patients with advanced soft tissue sarcoma after doxorubicin failure: an open-label, multi-centric phase II study not-yet-due
Ongoing 2010-018869-29 Phase II study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS / TGCT) not-yet-due
Ongoing 2010-023265-22 A randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy of afatinib (BIBW 2992) in maintenance therapy after postoperative concurrent radiotherapy and chemotherapy for... not-yet-due
No trial status on register 2010-023461-22 Efficacité et tolérance d’emplâtres de lidocaïne à 5% (Versatis® 5%) dans les douleurs neuropathiques et dans les douleurs de crises vaso-occlusives drépanocytaires de l’enfant, de l’adolescent et du ... bad-data
Exempt 2011-003372-37 An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presen... not-yet-due
Ongoing 2013-000076-16 BENEFIT - A multicenter phase II study evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) prior to autologous stem cell transplant for first and second chemosensitive relapses in patien... not-yet-due
Ongoing 2013-002766-39 SIOP Ependymoma II - An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with Ependymoma not-yet-due
Ongoing 2013-004039-60 A multicenter study to evaluate a risk-adapted strategy for treatment of extra cranial non seminomateous malignant germ cell tumour in children, adolescent and young adult not-yet-due
Ongoing 2016-002736-33 CHEMOIMMUNE - A Phase II study evaluating an anti-PD1 monoclonal antibody (pembrolizumab) in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide not-yet-due
Ongoing 2016-004537-25 An Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB monotherapy in patients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-... not-yet-due
Ongoing 2016-005019-42 A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas patient... not-yet-due
Ongoing 2017-002069-22 BREASTIMMUNE02 - A multicenter, randomized, open-label, Phase II trial aiming to evaluate the impact of pegfilgrastim on trastuzumab anti-tumor effect and antibody-dependent cell-mediated cytotoxicity... not-yet-due
Ongoing 2017-003151-34 A multicenter, randomised, open-label Phase II study to evaluate the clinical benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine... not-yet-due
Ongoing 2018-004045-16 REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone ... not-yet-due
Ongoing 2019-000678-41 CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases not-yet-due